多靶点抗肿瘤新药阿帕替尼的研究进展
作者：鲁丁瑜;李娜;李志平;
Author：
收稿日期： 年卷（期）页码：2017,32(01):-104-108
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：阿帕替尼;靶向治疗;肿瘤;血管内皮生长因子;血管内皮生长因子受体;血管生成;酪氨酸激酶抑制剂;多靶点
Key words：
基金项目：
中文摘要
抗肿瘤血管生成治疗在肿瘤治疗中发挥着重要作用,且大多数治疗是通过作用于血管内皮生长因子(VEGF)及其受体(VEGFR)的通路。大量临床前研究及临床试验表明:阿帕替尼对多种实体瘤包括胃癌、非小细胞肺癌、乳腺癌及肝癌等有广泛的抗肿瘤作用。结合近年的研究文献,就阿帕替尼的结构、机制、药物代谢动力学、在多种实体瘤中的相关临床试验及不良反应进行了综述。
参考文献
[1]Folkman J.Tumor angiogenesis:The tapeutic implications[J].New Engl J Med,1971,285(21):1182-1186.
[2]Fontanella C,Ongaro E,Bolzonello S,et al.Clinical advances in the development of novel VEGFR2 inhibitors[J].Ann Transl Med,2014,2(12):123.
[3]Hicklin DJ,Ellis LM.Role of thevascular endothelial growth factorpathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23:1011-1027.
[4]Tian S,Quan H,Xie C,et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase withpotent activity in vitro and in vivo[J].Cancer Sci,2011,102:1374-1380.
[5]Scott AJ,Messersmith WA,Jimeno A.Apatinib:A promising oral antiangiogenic agent in the treatment of multiple solid tumors[J].Drugs Today(Barc),2015,51(4):223-239.
[6]Zhang HJ.Apatinib for molecular targeted therapy in tumor[J].Drug Des Dev Ther,2015,9:6075-6081.
[7]Li J,Zhao X,Chen L,et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1in patients with advanced malignancies[J].BMC Cancer,2010,10:529.
[8]Ding J,Chen X,Gao Z,et al.Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2inhibitor apatinib in humans[J].Drug Metab Dispos,2013,41(6):1195-1210.
[9]丁珏芳,钟大放.小分子酪氨酸激酶抑制剂的临床药代动力学研究进展[J].药学学报,2013,48(7):1080-1090.
[10]Ding J,Chen X,Dai X,et al.Simultaneous determination of Apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study[J].J Chromatogr B Analyt Technol Biomed Life Sci,2012,895-896:108-115.
[11]Geng R,Li J.Apatinib for the treatment of gastric cancer[J].Expert Opin Pharmacother,2015,16(1):117-122.
[12]Mi YJ,Liang YJ,Huang HB,et al.Apatinib(YN968D1)reverses multidrug resistance by inhibiting the efflux function of multiple ATP binding cassette transporters[J].Cancer Res,2010,70(20):7981-7991.
[13]Tong XZ,Wang F,Liang S,et al.Apatinib(YN968D1)enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J].Biochem Pharmacol,2012,83(5):586-597.
[14]Li J,Qin S,Xu J,et al.Apatinib for chemotherapy-refractory advancedmetastatic gastric cancer:Results from a randomized,placebo-controlled,parallel-arm,phase II trial[J].J Clin Oncol,2013,31(26):3219-3225.
[15]Hu X,Zhang J,Xu B,et al.Multicenter phase II study of apatinib,anovel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J].Int J Cancer,2014,135(8):1961-1969.
[16]Hu X,Cao J,Hu W,et al.Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer,2014,14(1):1-8.
[17]Zhang L,Shi M,Huang C,et al.A phase II,multicenter,placebocontrolled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer(NSCLC)after two previous treatment regimens[J].J Clin Oncol,2012,30(Suppl):Abst 7548.
[18]Qin S.Apatinib in chinese patients with advanced hepatocellurcarcinoma:Aphase II randomized,open-label trial[J].ASCO Meeting Abstracts,2014,32(15-suppl).
[19]Qin S.Phase III study of apatinib in advanced gastric cancer:A randomized,double-blind,placebo-controlled trial[J].J Clin Oncol,2014,32(Suppl):Abst4003.
[20]Fan M,Zhang J,Wang Z,et al.Phosphorylated VEGFR2 and hypertension:Potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy[J].Breast Cancer Res Treat,2014,143(1):141-151.
[21]Van Cutsem E,de Haas S,Kang YK,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:Abiomarker evaluation from the AVAGAST randomized phase III trial[J].J Clin Oncol,2012,30(17):2119-2127.
【关闭】
